HOME HELP FEEDBACK ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by van Diemen, CleoC. Articles by Marike Boezen, H. Search for Related Content PubMed Articles by van Diemen, CleoC. Articles by Marike Boezen, H.

A Disintegrin and Metalloprotease 33 polymorphisms and lung function decline in the general population

^* Dept of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands ^# Dept of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands ^¶ Dept of Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

CORRESPONDENCE: Cleo C. van Diemen, Dept of Epidemiology, University of Groningen, University Medical Center, Groningen, The Netherlands

ADAM33 (A Disintegrin and Metalloprotease 33) has been identified as a susceptibility gene for asthma and single nucleotide polymorphisms (SNPs) in this gene have been associated with excess decline of lung function in asthmatics.

To assess whether SNPs in ADAM33 are associated with accelerated lung function loss in the general population and with chronic obstructive pulmonary disease (COPD).

We have collected DNA from subjects of the Vlagtwedde/Vlaardingen cohort participating in the last survey in 1989/1990 after a follow up of 25 years. Information was collected every 3 years, including lung function measurements. We defined COPD as GOLD stage 2 or higher at the last survey. 1390 subjects from the cohort were genotyped for the following SNPs in ADAM33: F+1, Q–1, S_1, S_2, T_1, T_2, V_4, ST+5. Differences in prevalence of SNPs were analyzed with chi-square tests. Linear mixed effects models were used to analyze FEV₁ decline according to genotype.

In the whole population mean adjusted decline was 18.7 and 12.7 ml·y^–1 in females and males respectively. Individuals homozygous for minor alleles of SNPs S_2 and Q–1 and heterozygous for SNP S_1 had a significantly accelerated decline in FEV₁ of respectively 4.9, 9.6 and 3.6 ml·y^–1 compared with wild type. We found a significantly higher prevalence of SNPs F+1, S_1, S_2 and T_2 in subjects with COPD.

We demonstrated that SNPs in ADAM33 are associated with accelerated lung function decline in the general population. These SNPs are also risk factors for COPD.